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Long-Term Prognosis of Adult Patients with Steroid-
Dependent Minimal Change Nephrotic Syndrome
Following Rituximab Treatment
Yuko Iwabuchi, MD, Takashi Takei, MD, PhD, Takahito Moriyama, MD, PhD,
Mitsuyo Itabashi, MD, PhD, and Kosaku Nitta, MD, PhD
Abstract: This study was to evaluate the long-term efficacy and safety
of a single-dose rituximab regimen rituximab treatment in adult patients
with steroid-dependent minimal change nephrotic syndrome (MCNS).
We conducted a prospective cohort study with historical controls to
evaluate the effect of single-dose infusions of rituximab at 375mg/m2
BSA per dose administered at intervals of 6 months for a period of 24
months. At the end of the 24-month period, the patients were divided
into the treatment continuation (n¼ 20) and treatment discontinuation
(n¼ 5) groups according to their intention to continue/discontinue the
treatment.
A significant reduction in the total number of relapses was
observed during the 24-month period after the first rituximab infusion
as compared with that during the 24-month period before the first
rituximab infusion (108 vs. 8, P< 0.001). Complete remission was
induced/maintained in all patients from 12 to 24 months after the first
rituximab infusion. In regard to the clinical course after 24 months,
4 of the 20 patients in the treatment continuation group discontinued
the rituximab treatment after the fifth infusion and 2 patients dis-
continued the treatment after the sixth infusion. However, complete
remission was maintained in all the 20 patients of this group during
the 12-month observation period after the first four single-dose
rituximab infusions. On the other hand, 1 of the 5 patients in the
treatment discontinuation group developed relapse during the obser-
vation period after the first four rituximab infusions, and the ritux-
imab treatment was resumed.
In our trial, rituximab therapy was associated with maintenance
of complete remission. Complete remission was maintained even in
most of the patients who showed B-cell repletion after discontinu-
ation of rituximab therapy. Thus, rituximab may be considered as a
radical therapeutic agent for patients with steroid-dependent
MCNS.
(Medicine 93(29):e300)
Abbreviations: CyA = cyclosporine, CYC = cyclophosphamide,
MCNS = minimal change nephrotic syndrome, MMF =
mycophenolate mofetil, MZ = mizoribine, RRED = prednisolone,
TAC = tacrolimus.
INTRODUCTION
S teroid-dependent minimal change nephrotic syndrome(MCNS) necessitates the administration of prolonged
courses of treatment with prednisolone (PRED). Therefore,
most of these patients require the addition of another immu-
nosuppressive drug(s), such as cyclosporine (CyA), tacrolimus
(TAC), mycophenolate mofetil (MMF), cyclophosphamide
(CYC) or mizoribine (MZ), to reduce the number of relapses
and prevent the major side effects of steroid treatment.1 How-
ever, these immunosuppressive medications may be unable to
induce remission and may also have significant adverse effects
of their own.2,3 Recently, a number of publications have
reported the usefulness of rituximab for the treatment of MCNS
in pediatric patients,4–13 while there are fewer reports, includ-
ing our previous reports, of treatment in the adult setting.14 The
rituximab doses used for the treatment of steroid-dependent
MCNS in these studies vary greatly, from a single flat dose of
500 or 1000mg at 1 or 2 time-points, to 375mg/m2 BSA once
weekly for 4 weeks. It is difficult to draw any robust conclusions
about the optimal dosing schedule of rituximab from these
previous reports.
We published the results of a prospective trial of the effects
of a single dose of rituximab administered twice at an interval of
6 months in 25 steroid-dependent MCNS patients.14 Herein, we
report the results of our prospective study carried out to examine
the long-term efficacy and safety of single-dose administrations
of rituximab at intervals of 6 months for a period 24-months,
and also the clinical courses of the patients after the rituximab
treatment for 24 months in patients with steroid-dependent
MCNS.
METHODS
Patient Population
Patients fulfilling the following criteria were enrolled in
this study: Patients with steroid-dependent nephrotic syndrome,
defined as the occurrence of relapse during the tapering down or
within 2 weeks of discontinuation of PRED. Nephrotic syn-
drome was defined as urinary protein excretion of 3.5 g/day,
serum albumin of <3.0 g/dL, edema, and hyperlipidemia.
Relapse was defined as recurrence of massive proteinuria (daily
urinary protein excretion of3.5 g/day or 3þ or 4þ result of the
urine albumin dipstick test for albumin); biopsy-proven diag-
nosis of minimal-change disease; no known associated systemic
disease, including negative serology for hepatitis B and C, HIV
and antinuclear antibodies, and no positive family history; no
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previous history of rituximab treatment. The study was con-
ducted with the approval of the Research Ethics Board of Tokyo
Women’s Medical University. All the patients gave written
informed consent for participation in the study. Between March
2008 and December 2013, 25 patients (21 male and 4 female)
with steroid-dependent MCNS were enrolled for the study at
our department.
The mean time period from the diagnosis until the start of
rituximab treatment was 13 8 years. All of the patients had
experienced relapses before, with a maximum of 129 relapses
during the 24-month period prior to the first rituximab injec-
tion. Seven patients (28%) had nephrotic syndrome, 3 patients
(12%) were in partial remission, and 15 patients (60%) were in
complete remission at the time of start of the rituximab
treatment. ‘‘Complete remission’’ was defined as clinical
improvement or a daily urinary protein excretion of <0.3 g
as judged by a trace or negative result of the urine dipstick test
for albumin. ‘‘Partial remission’’ was defined by a daily
urinary protein excretion of <3.5 g, below nephrotic range,
with a relative increase of the serum albumin. The mean age of
the patients at the time of start of rituximab treatment was
29 12 years. The clinical data were examined according to
the presence/absence of a history of treatment with steroids
and/or conventional immunosuppressant drugs. Previously
used immunosuppressant drugs in the patients, besides the
steroid, included CyA (n¼ 20), MZ (n¼ 6), MMF (n¼ 1), and
TAC (n¼ 1); 28 patients were receiving a steroid (PRED
24.2 12.4mg/day; dose range 5–60mg/day) at the time of
start of the rituximab treatment.
Treatment
The first rituximab dose was administered by intravenous
infusion at a single dose of 375mg/m2 BSA. In order to
minimize the infusion reactions, we administered 4mg of
betamethasone, 20mg of monoammonium glycyrrhizinate,
and 200mg of acetaminophen to the patients 30minute prior
to the rituximab infusion. The rituximab infusion was repeated 4
times at 6-month intervals, that is, at 6 months, 12 months, and
18 months after the first infusion (a biannual, single-dose
rituximab regimen 24 months, Figure 1). Thereafter, the
patients were divided into two groups according to their inten-
tion to continue/discontinue the treatment, namely, the treat-
ment continuation group (n¼ 20) and the treatment
discontinuation group (n¼ 5). The patients of the treatment
continuation group continued to receive the rituximab infusions
at 6-month intervals according to the same dosing protocol.
None of the patients received concomitant medications, includ-
ing prophylaxis for Pneumocystis jiroveci (trimethoprim/sulfa-
methoxazole).
Follow-Up
The following laboratory parameters were examined in all
the patients. An attempt was made to taper the steroid dose/
discontinue the steroid by 24 months after the first rituximab
injection, although no precise protocol was set for tapering the
steroid dose. There were no restrictive protocols for discon-
tinuation of either the immunosuppressants or PRED in this
trial. Patients were followed up for at least 36 months after the
first rituximab injection. B-cell depletion was defined as a
peripheral blood CD19 count of <10/mm3 and B-cell repletion
was defined as a peripheral blood CD19 count of >10mm3. In
addition, the cumulative dose of PRED, number of patients
requiring PRED, CyA, MMF, or MZ, bone density (Bone
Mineral Density [BMD] and Z score), and total number of
relapses were evaluated at the baseline, during the 24-month
period before the first rituximab infusion, and during the 24-
month period after the first rituximab infusion. We also com-
pared the clinical courses of the patients after the first 24 months
in the treatment continuation and treatment discontinuation
groups. The primary endpoints were the number of relapses
1st Rituximab
e.g.
e.g.
2nd Rituximab 3rd Rituximab 4th Rituximab
baseline 12 months 18 months6 months
Immunosupresants
PRED
24 months 30 months 36 months
Study Protocol
(Rituximab) (Rituximab) (Rituximab)
FIGURE 1. Study protocol. Rituximab was administered by intravenous injection at the dose of 375mg/m2 BSA at the baseline, and at 6,
12, and 18 months after the first dose. Thereafter, rituximab treatment was continued or discontinued. No precise protocol was set for
tapering the steroid dose. There were no restrictive protocols for discontinuation of either the immunosuppressants or PRED.
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and number of patients requiring PRED and/or immunosup-
pressant drugs. The second endpoints were the frequency and
severity of the adverse events of PRED, including osteoporosis,
and those of rituximab.
Statistical Analysis
Datawere expressed asmeans standard deviation (SD). All
analyzed variables were tested for distribution. The t test was used
for samples with a normal distribution and the Mann–Whitney U
test for samples with a skewed distribution, to analyze the
differences in the laboratory data recorded between the baseline
and at 1 month and 6 months after the first rituximab injection.
Categorical data were analyzed by the x2 test. All the statistical
analyses were performed using the JMP 9 software (SAS Institute,
Cary, NC). Statistical significance was set at P< 0.05.
RESULTS
Rituximab Treatment (Biannual, Single-Dose
Rituximab Regimen T24 months)
The characteristics of the patients at the baseline (at the
time of the first rituximab injection) and the clinical courses of
the patients after the first rituximab injection are shown in
Table 1. Complete remission was achieved within 1 month of
the first rituximab infusion in all the 7 patients who had
nephrotic syndrome at the baseline. Six relapses occurred
during the first 6 months of follow-up (between the first and
second rituximab doses), and 2 relapses occurred during the 6-
to 12-month period after the first rituximab dose (between the
second and third rituximab doses), however, no relapses
occurred during the 1-year period from 12 to 24 months after
the first rituximab infusion. Comparison of the total number of
relapses between the 24-month period before the first rituximab
injection and the 24-month period after the first rituximab
injection revealed a significantly lower number of relapses
during the latter period (108 vs. 8; P< 0.01) (Figure 2).
Significant decreases of the urinary protein excretion,
serum total cholesterol and CD19/CD20 counts, and significant
increase of the serum albumin were found at all the measure-
ment points during the 24-month period after the first rituximab
dose, as compared to the values recorded at the baseline. No
significant changes in the serum creatinine levels were noted
during the trial period.
The steroid could be discontinued by 24 months after the
first rituximab administration in all the patients who were
receiving a steroid at the time of the first rituximab infusion.
In all of the patients, tapering of the PRED dose could be begun
after the first administration of rituximab. The number of
patients requiring PRED and/or immunosuppressant drugs
was compared between the baseline and at the end of 24 months
after the first rituximab infusion. The number of patients
requiring PRED as well as the mean daily PRED dose was
significantly lower (number of patients requiring PRED, 25 vs.
4; P< 0.001; mean daily PRED dose, 24.2 12.4 vs. 0.6 1.3;
P< 0.001) at the end of 24 months after the first rituximab
administration. The numbers of patients requiring CyA and MZ
TABLE 1. Change in Clinical Parameters in Steroid Dependent Minimal Change Nephrotic Syndrome
Parameters
Baseline
(1st Rituximab) 1 Month
6 Month (2nd
Rituximab)
12 Month (3rd
Rituximab)
18 Month (4th
Rituximab) 24 Month 36 Month
Sex (female:men) 4:21
Age (years) 30.1 11.9
Systolic blood pressure
(mmHg)
123 13 117 12þ 119 12þ 117 12þ 118 15 112 11þ 117  14þ
Diastolic blood pressure
(mmHg)
76 11 70 11þ 70 12þ 71 13þ 73 14þ 68 10þ 69 14þ
Urinary protein (g/day) 2.5 4.9 0.1 0.3þ 1.8  4.0þ 1.3 4.8 0 0þ 0 0þ 0 0þ
Serum albumin (g/dL) 3.6 0.8 4.0 0.6þ 4.0 0.7þ 4.3 0.7þ 4.5 0.3þ 4.6 0.3þ 4.5 0.3þ
Total-cholesterol (mg/dL) 262 79 212 55þ 212 70þ 196 51þ 191 95þ 179 41þ 166 30þ
Serum creatinine (mg/dL) 0.7 0.2 0.7 0.1 0.7 0.2 0.7 0.2 0.7 0.1 0.7 0.1 0.7 0.1
IgG (mg/dL) 705 274 847  233þ 990 232þ 984 257þ 1028 248þ 1010 261þ 928 264
CD19 (/mm3) 98 104 2.5 2.6þ 26 37þ 31 89þ 13 29þ 11 17þ 21 45þ
CD20 (/mm3) 101 97 1.8 1.2þ 27 36þ 33 78þ 13 36þ 11 19þ 22 51þ
The depletion of
B cell (n)
0 25 18 18 22 21 21
CD4/8 1.1 0.4 1.0 0.5 1.2 0.4 1.3 0.4 1.5 0.4þ 1.4 0.4þ 1.4 0.4þ
IL-4 13 15 30 62 27 55 28 71 25 60 30 70 37 104
TNF-a 1.1 0.3 1.0 0.4 1.1 0.4 1.4 1.8 1.7 2.4 1.2 0.4 1.3 0.4
Th1/Th2 40 88 43 85 43 144 12 14 13 15 13 21 11 12
Nephrotic syndrome (n) 7 0 6 2 0 0 0
PRED (mg/dL) 24.0 (5–60) 13.8þ (0–40) 5.6þ (0–20) 4.5þ (0–40) 1.3þ (0–5) 0.6þ (0–2.5) 0.6þ (0–5)
PRED (n) 25 22 13 8 6 4 5
CyA (n) 20 19 16 11 7 5 3
MMF (n) 1 1 1 3 2 2 1
MZ (n) 6 6 5 1 0 0 0
TAC (n) 1 1 1 0 0 0 0
BMD (g/cm2) 0.84 0.20 0.95 0.10þ
Z-score 1.7 1.5 0.7 1.0þ
BMD¼ bone mineral density, CyA¼ cyclosporine, MZ¼mizoribine, PRED¼ prednisolone, TAC¼ tacrolimus.
Pþ value: significantly different from baseline. Values are expressed as meanSD. P< 0.05.
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were also significantly lower (CyA, 20 vs. 5; P< 0.001; MZ, 6
vs. 0; P< 0.001). TAC could be discontinued by 24 months
after the first rituximab administration in all patients. To assess
the improvement in the adverse effects of PRED, we measured
the bone density at the baseline and at 24 months after the first
rituximab administration. The BMD (g/m2) and Z scores were
significantly higher at 24 months as compared with the values
recorded at the baseline (0.84 0.2 vs. 0.95 0.10; P< 0.05,
1.7 1.5 vs. 0.7 1.0; P< 0.01).
Long-Term Outcomes
Complete remission was maintained in all patients at the
end of 24 months after the first infusion of rituximab (Table 2).
Of the 20 patients who continued to receive the 6-monthly
rituximab infusions after 24 months (treatment continuation
group), 4 discontinued the rituximab treatment after the fifth
infusion and 2 discontinued the treatment after the sixth infusion
of their own will; however, complete remission was maintained
in all the 20 patients from 36 to 54 months after the first
rituximab infusion. In the treatment discontinuation group,
1 of the 5 patients developed relapse with B-cell repletion at
8 months after the last rituximab infusion, and the rituximab
treatment was resumed.
B-Cell Depletion
The peripheral blood B-cell count increased significantly
by 6 months after the first infusion in 18 of the 25 patients
(Figure 3). Furthermore, 6 of these 18 patients developed
relapse by around 6 months after the first rituximab infusion.
The B cell count increased again by 6 months after the 2nd
rituximab infusion in 7 of the 25 patients; 2 of these 7 patients
developed relapse by around 6 months after the 2nd rituximab
infusion. Thereafter, complete B-cell depletion was achieved
again in all the 25 patients after the 3rd and after the 4th
rituximab infusions, and significant increase of the peripheral
blood B cell count occurred in 3 patients by 6 months after the
3rd rituximab infusion and in 4 patients by 6 months after the
4th infusion. However, none of these patients developed relapse
by 18 or 24 months after the first rituximab infusion.
In 3 of the 20 patients of the treatment continuation group,
the B-cell counts increased at 30 months after the first rituximab
infusion, however, none of these patients developed relapse.
Furthermore, 2 of the 16 patients who continued the treatment
after the 5th rituximab infusion showed an increase of the B-cell
count at 36 months after the first rituximab infusion, although
neither of these patients developed relapse either relapse. In
addition, 1 of the 14 patients who received the 7th rituximab
infusion showed increase of the B-cell count at 42 months after
the first rituximab infusion, and this patient did not show relapse
either. In all of the 5 patients of the treatment discontinuation
group (treatment discontinued after the 4th rituximab infusion),
the B-cell count increased from 6 to 10 months after the 4th
rituximab infusion; 1 (patient No. 2) of these patients was
increased B-cell count by around 10 months after the last
rituximab infusion, and the rituximab treatment was resumed
in consideration of relapse at 13 months after the last rituximab
infusion. In the remaining 10 patients with B-cell repletion
(including 4 from the treatment discontinuation group and 6
from the treatment continuation group) complete remission was
maintained despite the B-cell repletion.
Adverse Events
Of the 133 infusions in 25 patients, 13 infusions (9.8%) in 9
patients (36%) were associated with adverse events, including
mild infusion reactions such as cough and hiccups. One patient
developed exanthema almost immediately after the start of
administration of rituximab, which was observed as a fixed
drug eruption on the trunk and improved following treatment
with betamethasone. One patient developed leukopenia (white
blood cell count less than 3000/mm3) at 9 months from the
baseline, and the white blood cell count improved to 5000/mm3
by 12 months. There were no severe adverse events, such as
infectious episodes or hematological toxicities during the study
period. Caution is needed in respect of the risk of late compli-
cations such as multifocal progressive leukoencephalopathy.
DISCUSSION
Rituximab which is known to cause B-cell depletion has
been shown to have significant efficacy against immunological
disorders caused by autoantibodies.15 Several reports have
suggested the possible efficacy of rituximab in pediatric patients
with nephrotic syndrome.4–13 In our previous study, we demon-
strated that rituximab exerted almost the same efficacy in adult
patients with steroid-dependent MCNS.14 More recently pub-
lished studies have also reported the efficacy of this drug in
adult patients withMCNS.16–18 In one reported study, there was
no difference in the efficacy of rituximab between patients with
adult and childhood onset of the disease.18
The rituximab doses used vary greatly among reports. In
most studies, rituximab was given at the dose of 375mg/m2
BSA once a week for 4 weeks.6,19 In most cases of relapse, the
relapse developed simultaneously with the recovery of the B-
cell count.5 The time to recovery of the B-cell counts ranged
from 5 to 10 months (average 7.5 months). Therefore we
administered single-dose infusions of rituximab at intervals
of 6 months and demonstrated the efficacy of two doses of
rituximab.14
We observed significant increases of the B-cell counts by
6 months after the 1st rituximab infusion in 18 patients,
by 6 months after the 2nd rituximab infusion in 7 patients,
by 6 months after the 3rd infusion in 7 patients, and by 6 months
after the 4th rituximab infusions in 7 patients (Figure 3). Six of
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the 18 patients who showed an increase of the B-cell count by
6 months after the 1st rituximab infusion and 2 of the 7 patients
who showed an increase of the B-cell count by 6 months after
the 2nd rituximab infusion developed relapse. In all of the
5 patients of the treatment discontinuation group who discon-
tinued rituximab after the 4th rituximab infusion, the B-cell
count increased again by 6 months after the 4th rituximab
infusion, and 1 of these 5 patients developed relapse. On the
other hand, remission was maintained in all of the patients in
whom B-cell depletion was maintained. Interestingly, complete
remission was also maintained in the 10 patients who showed B-
cell repletion after discontinuation of the rituximab therapy.
There is a possibility that depletion of B cells for 24 months
influenced the improvement of the morbidity of steroid-depen-
dent MCNS, suggesting that B-cell restitution is always associ-
ated with relapse.
Rituximab therapy could facilitate reduction of the steroid
and immunosuppressant drug doses. The reduced exposure to
steroid and CyA most likely accounted for the progressive
reduction of the blood pressure and amelioration of dyslipide-
mia observed during the observation period in our study.
Rituximab significantly blunted the progressively increasing
bone density deficit observed following long-term steroid
exposure, with normalization of the bone density by the end
of the 2-year observation period. The risk of infections was
probably reduced because of the increased IgG and CD4/8 ratio.
There were no cases of severe infection during the observation
period. The therapy for steroid-dependent MCNS was recom-
mended using the CYC or CyA.20 However rituximab therapy
should be preferentially used for patients with a risk of adverse
effect of immunosuppressive medications such as PRED, CYC,
and CyA.
B-lymphocytes may play an important regulatory and
potentially pathogenic role in MCNS through antibody-inde-
pendent mechanisms such as antigen presentation, T-lympho-
cyte activation, and production of cytokines. Imbalance
between T-helper 1 (Th1) and 2 (Th2) lymphocytes (Th1/
Th2 imbalance) has been implicated in the development of
MCNS, and a Th2 shift caused by increased IL-4 has been
observed.21 In this study, while a tendency towards a Th2 shift
caused by increased IL-4 was observed, pathogenesis remained
unclear and further research is required. There are detailed
reports on the rate and phenotype of B-lymphocyte subpopu-
lation recovery after rituximab treatment in patients with
25 patients with 1st rituximab treatment 
Remission 25 patients
Remission 19patients Relapse 6 patients
B cell repletion
12 patients
B cell depletion
7 patients 
B cell depletion 
25 patients
Remission 25 patients
Remission 25 patients
Remission 25 patients
Remission 25 patients
Remission 25 patients
Remission 23patients Relapse 2 patients
25 patients with 2nd rituximab treatment 
25 patients with 3rdrituximab treatment 
25 patients with 4th rituximab treatment 
B cell depletion 
25 patients
B cell depletion 
25 patients
B cell depletion 
25 patients 
B cell repletion
5 patients
B cell depletion
18 patients 
B cell repletion
3 patients
B cell depletion
22 patients 
B cell repletion
4 patients
B cell depletion
21 patients 
B cell repletion 
6 patients
B cell repletion 
2 patients
Relapse
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No relapse
4 patients
Relapse
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6thor more RTX
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B cell 
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FIGURE 3. Study flow chart.
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rheumatoid arthritis: after B-cell depletion, immature B
lymphocytes reappear first, followed by naı¨ve B lymphocytes;
CD27þ memory B lymphocytes may remain depleted for up to
2 years after a single dose of rituximab.22 It has also been
reported that rituximab may have the effect of stabilizing the
podocyte cytoskeleton and decreasing proteinuria through this
mechanism,23 however the pathophysiological mechanism
underlying the efficacy of rituximab against MCNS remains
unclear.
In our trial, rituximab therapy was associated with main-
tenance of complete remission. The limitations of this study
were that it was not a randomized controlled trial and the
number of patients enrolled was small. Complete remission
was maintained in all the patients showing B-cell depletion.
Complete remission was also maintained in most of the patients
with B-cell repletion following discontinuation of rituximab
therapy after B-cell depletion had been maintained for at least
12 months. Thus, rituximab treatment may be considered as a
radical therapeutic agent for patients with steroid-dependent
MCNS.
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